Inclusion Criteria:

- Have a diagnosis of adult-onset RA of at least 6 months' (24 weeks) duration as
defined by the 1987 ACR classification criteria or a score of ≥6 as defined by the
ACR/European League Against Rheumatism Classification and Diagnostic Criteria for RA

- Must have moderately to severely active RA disease as defined by ≥6 tender joints
(68-joint count) at Screening and Baseline, ≥6 swollen joints (66-joint count) at
Screening and Baseline, CRP ≥1.2 times the upper limit of normal (ULN) or ESR
>28mm/hour

- Must be on an MTX dose of 6 to 16mg/week in Japan or 7.5 to 20mg/week in Korea and
Taiwan, which has been stable for at least 6 weeks prior to Screening with a stable
route of administration

- Must have had intolerance or inadequate response to treatment with 1 or more
TNF-blocker therapies within 2 years of Screening

- Female subjects must be either postmenopausal for at least 1 year, surgically
incapable of childbearing, or effectively practicing 2 acceptable methods of
contraception

Exclusion Criteria:

- Have a diagnosis of any other inflammatory arthritis

- Female subjects who are breast-feeding, pregnant, or plan to become pregnant during
the study or within 24 weeks

- Disease modifying antirheumatic drug (DMARDs) other than methotrexate (MTX)

- Subjects with known concurrent acute or chronic viral hepatitis B or C infection

- Subject has known tuberculosis (TB) disease, high risk of acquiring TB infection, or
latent TB infection

- Subjects with known history of or current clinically active infection

- Subjects at high risk of infection

- Subjects with known human immunodeficiency virus (HIV) or human T cell lymphotropic
virus type 1 (HTLV 1) infection

- Have received vaccinations within 8 weeks prior to Screening or plan to receive
vaccines during the study (with the exception of injectable influenza and
pneumococcal vaccinations which are permitted)

- Concurrent malignancy or a history of malignancy (with the exception of successfully
treated carcinoma of the cervix more than 5 years prior to Screening or no more than
2 successfully treated basal cell carcinomas within 2 years prior to Screening